Business and Financial Review • Jan 7, 2016
Business and Financial Review
Open in ViewerOpens in native device viewer
As part of the liquidity contract entrusted by ONXEO to CM-CIC, the following assets appeared on the liquidity account as of December 31, 2015:
As a reminder, as of June 30, 2015, the following assets appeared on the liquidity account:
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad® ): Phase II in severe oral mucositis: Positive final results Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com
Contacts : Nathalie Delair-Trepo Investor Relations, Onxeo [email protected] +33 1 45 58 76 00
Caroline Carmagnol / Florence Portejoie – Alize RP (France) [email protected] +33 6 64 18 99 59 / +33 1 44 54 36 64
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.